Valuation: Sionna Therapeutics, Inc.

Market Cap 151M 137M 126M 114M 215M 14.2B 222M 1.52B 601M 7.59B 565M 553M 24.08B P/E 2026 *
-1.3x
P/E 2027 * -1.48x
Enterprise Value 54.16M 49.08M 45.39M 40.96M 77.18M 5.11B 79.9M 545M 216M 2.73B 203M 199M 8.66B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Sionna Therapeutics, Inc.

1 day-2.92%
1 week+1.52%
Current month-13.95%
1 month-18.58%
3 months-48.45%
6 months-92.21%
Current year-91.91%
1 week 3.22
Extreme 3.22
3.86
1 month 3.19
Extreme 3.19
4.31
Current year 3.19
Extreme 3.19
54.97
1 year 3.19
Extreme 3.19
54.97
3 years 3.19
Extreme 3.19
54.97
5 years 3.19
Extreme 3.19
54.97
10 years 3.19
Extreme 3.19
54.97
Manager TitleAgeSince
Corporate Officer/Principal - 01/08/2019
Corporate Officer/Principal - 01/08/2019
Chief Executive Officer 55 01/05/2021
Director TitleAgeSince
Director/Board Member 51 01/12/2019
Director/Board Member 44 01/12/2019
Director/Board Member 52 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 A Free

General Counsel

262,545 0.5807%
9/17/26 A Free

Chief Financial Officer

425,417 0.9409%
9/17/26 A Free

Chief Technology Officer

411,400 0.9099%
Change 5-day change 1-year change 3-year change Capi.($)
-2.92%+1.52%-91.00% - 151M
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+12.64%+92.55% 60.62B
0.00%+0.39%+22.34%+90.83% 55.5B
+0.14%+2.35%+13.86%+106.64% 47.58B
-2.21%-2.47%+20.18%+32.24% 43.69B
-2.30%-10.40%+154.30%+725.54% 37.27B
+2.15%+1.42%+14.58%+54.23% 36.57B
-2.32%-2.24%+76.50%+54.55% 32.22B
+2.62%+5.90%-37.29%+393.72% 26.58B
Average -0.84%+0.20%+24.01%+180.14% 41B
Weighted average by Cap. -0.83%+0.20%+36.58%+155.25%

Financials

2026 *2027 *
Net sales - -
Net income -116M -105M -97.23M -87.72M -165M -10.94B -171M -1.17B -463M -5.84B -435M -426M -18.55B -109M -98.84M -91.42M -82.48M -155M -10.28B -161M -1.1B -435M -5.49B -409M -401M -17.44B
Net Debt -96.48M -87.43M -80.87M -72.96M -137M -9.1B -142M -971M -385M -4.86B -362M -354M -15.42B -233M -211M -195M -176M -332M -21.99B -344M -2.35B -931M -11.74B -875M -857M -37.28B
Projected Income Statement - Annual - Sionna Therapeutics, Inc.
Logo Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Employees
59
Date Price Change Volume
13/11/26 $3.330 -2.92% 470,236
12/11/26 $3.430 -7.30% 411,800
11/11/26 $3.700 0.00% 647,134
10/11/26 $3.700 +3.64% 954,804
09/11/26 $3.570 +8.84% 1,089,770
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Sionna Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
3.330USD
Average target price
21.00USD
Spread / Average Target
+530.63%
  1. Stock Market
  2. Stocks
  3. SION Stock